Stockscreener 앱 받기
31.31
3.07%
-0.99
전일 마감가:
$32.30
열려 있는:
$31.81
하루 거래량:
1.93M
Relative Volume:
0.93
시가총액:
$19.29B
수익:
$2.62B
순이익/손실:
$966.70M
주가수익비율:
20.87
EPS:
1.5004
순현금흐름:
$1.09B
1주 성능:
-1.35%
1개월 성능:
+2.76%
6개월 성능:
+35.60%
1년 성능:
+51.62%
1일 변동 폭
$31.24
$31.90
1주일 범위
$30.81
$32.51
52주 변동 폭
$17.23
$33.65
Genmab Adr Stock (GMAB) Company Profile
GMAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
31.31 | 19.90B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-04-01 | 다운그레이드 | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-04 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-08-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-15 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-12-06 | 업그레이드 | UBS | Neutral → Buy |
| 2023-11-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-11-08 | 업그레이드 | DNB Markets | Sell → Buy |
| 2023-10-18 | 개시 | Exane BNP Paribas | Underperform |
| 2023-09-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 개시 | BTIG Research | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-31 | 개시 | UBS | Neutral |
| 2023-05-12 | 개시 | Morgan Stanley | Underweight |
| 2022-12-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-11-14 | 개시 | William Blair | Mkt Perform |
| 2022-11-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 개시 | BMO Capital Markets | Market Perform |
| 2022-05-02 | 개시 | Cowen | Market Perform |
| 2022-03-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-12-01 | 개시 | Berenberg | Sell |
| 2021-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 개시 | Deutsche Bank | Buy |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | 다운그레이드 | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 개시 | SVB Leerink | Mkt Perform |
| 2020-06-25 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 개시 | Credit Suisse | Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-12 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-09-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | Morgan Stanley | Overweight |
| 2019-08-12 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Genmab Adr 주식(GMAB)의 최신 뉴스
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - GlobeNewswire Inc.
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 86,842 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Bought by First Trust Advisors LP - Defense World
Quoin Pharm ADR Joins Rank Of Stocks With RS Ratings Over 90 - MSN
Marshall Wace LLP Cuts Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Sold by American Century Companies Inc. - Defense World
AI Plays Lead Five Stocks To Watch Near Buy Points - Investor's Business Daily
Arrowstreet Capital Limited Partnership Raises Position in Genmab A/S Sponsored ADR $GMAB - Defense World
JPMorgan Chase & Co. Grows Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter - Investor's Business Daily
Genmab A/S Sponsored ADR $GMAB Position Reduced by Russell Investments Group Ltd. - MarketBeat
Capital Fund Management S.A. Has $4.68 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Arbor Realty Trust Inc (ABR): What is the Risk Factor? - fostersleader.com
Level Four Advisory Services LLC Acquires 12,888 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Rockefeller Capital Management L.P. Purchases New Shares in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Purchased by Creative Planning - Defense World
AlphaCore Capital LLC Invests $44,000 in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR $GMAB Shares Sold by PNC Financial Services Group Inc. - MarketBeat
Genmab ADR Earns Membership In 95-Plus Composite Rating Club - MSN
AIMZ Investment Advisors LLC Has $3.43 Million Position in Genmab A/S Sponsored ADR $GMAB - Defense World
Stocks To Watch: Immunocore Holdings ADR Sees RS Rating Rise To 83 - MSN
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Vera Therapeutics Stock Earns RS Rating Upgrade - Investor's Business Daily
Q1 Earnings Estimate for Genmab A/S Issued By HC Wainwright - Defense World
Ocular Therapeutix Stock Earns 81 RS Rating - Investor's Business Daily
FY2025 EPS Estimates for Genmab A/S Raised by HC Wainwright - Defense World
Syndax Pharmaceuticals Stock Earns RS Rating Upgrade - Investor's Business Daily
Leerink Partnrs Forecasts Weaker Earnings for Genmab A/S - Defense World
Stocks With Rising Relative Strength: Immunocore Holdings ADR - Investor's Business Daily
FY2025 EPS Estimates for Genmab A/S Raised by William Blair - Defense World
Genmab A/S Sponsored ADR $GMAB Position Reduced by Y Intercept Hong Kong Ltd - Defense World
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - MSN
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S Sponsored ADR $GMAB Shares Sold by Ingalls & Snyder LLC - MarketBeat
William Blair Predicts Genmab A/S FY2027 Earnings - Defense World
Short Interest in Genmab A/S Sponsored ADR (NASDAQ:GMAB) Increases By 59.3% - MarketBeat
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Genmab Adr (GMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.72%
0.91%
자본화:
|
볼륨(24시간):